About Viral Conjunctivitis Drugs
Viral conjunctivitis, or pink eye, is a type of infectious conjunctivitis that is commonly caused by an adenovirus. Herpes simplex virus (HSV), picornavirus (enterovirus 70, Coxsackie A24), varicella-zoster virus, poxvirus (molluscum contagiosum and vaccinia), and human immunodeficiency virus (HIV) are some of the other viruses that are responsible for the infection. Discomfort through watery discharge is the main symptom of this highly contagious condition. It is often associated with keratoconjunctivitis, which results in slightly blurred vision. No specific treatment option is available for the infection, which heals by itself in 2-3 weeks. Antibiotics and anti-inflammatory drugs are used only if the condition persists. In certain instances, when the infection is serious or persists for weeks, topical antiviral drugs are used. Corneal lesions persist for months even after the condition heals.
Technavios analysts forecast the global viral conjunctivitis drugs market to grow at a CAGR of 2.41% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global viral conjunctivitis drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of viral conjunctivitis.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Viral Conjunctivitis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Akorn
• Alcon
• Allergan
• Bausch & Lomb
Other prominent vendors
• Adenovir Pharma
• Marinomed Biotechnologie
• Mediolanum Laboratoires
• NanoViricides
• Nicox
• Novartis
• Panoptes Pharma
• Rapid Pathogen Screening
• Shire
• Starpharma
• Valeant Pharmaceuticals
Market driver
• Rising awareness
• For a full, detailed list, view our report
Market challenge
• Low diagnosis rate
• For a full, detailed list, view our report
Market trend
• Use of off-label drugs
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Conjunctivitis
Viral conjunctivitis
Signs and symptoms
Diagnosis
Management
Epidemiology
Economic burden
PART 06: Pipeline analysis
FST-100
APD-209 eye drops
SPL7013
EKC-Cide
PP-001
PART 07: Market landscape
Market overview
Market size and forecast
Viral conjunctivitis drugs market in US
Five forces analysis
PART 08: Market segmentation by route of administration
Topical
Oral
Intravitreal
PART 09: Geographical segmentation
Global viral conjunctivitis drugs market by geography 2015-2020
Viral conjunctivitis drugs market in Americas
Viral conjunctivitis drugs market in EMEA
Viral conjunctivitis drugs market in APAC
PART 10: Market drivers
Rising awareness
Unmet needs for viral conjunctivitis
High prevalence
PART 11: Impact of drivers
PART 12: Market challenges
Low diagnosis rate
Adverse effects and limited efficacy of drugs
Satisfaction with existing therapies
Availability of alternative therapies
PART 13: Impact of drivers and challenges
PART 14: Market trends
Strategic alliances and M&A
Use of off-label drugs
Rise in R&D
PART 15: Vendor landscape
Akorn
Alcon
Allergan
Bausch & Lomb
Other prominent vendors
PART 16: Appendix
List of abbreviations
PART 17: Explore Technavio
?
Exhibit 01: Product offerings
Exhibit 02: Types of conjunctivitis
Exhibit 03: Major types of viral conjunctivitis
Exhibit 04: Signs and symptoms of types of viral conjunctivitis
Exhibit 05: Diagnostic algorithm for viral conjunctivitis
Exhibit 06: Drugs used to treat conjunctivitis
Exhibit 07: Comparison of prevalent rates in different types of conjunctivitis among adults and pediatric population (%)
Exhibit 08: Global viral conjunctivitis drugs market: Pipeline portfolio
Exhibit 09: Global viral conjunctivitis drugs market 2015-2020 ($ millions)
Exhibit 10: Snapshot of global viral conjunctivitis drugs market
Exhibit 11: Percentage share of US in the global viral conjunctivitis drugs market 2015
Exhibit 12: Viral conjunctivitis drugs market in US 2015-2020 ($ millions)
Exhibit 13: Five forces analysis
Exhibit 14: Global viral conjunctivitis drugs market segment by route of administration
Exhibit 15: Global viral conjunctivitis drugs market by geography 2015
Exhibit 16: Viral conjunctivitis drugs market by geography 2015-2020 ($ millions)
Exhibit 17: Viral conjunctivitis drugs market in Americas 2015-2020 ($ millions)
Exhibit 18: Viral conjunctivitis drugs market in EMEA 2015-2020 ($ millions)
Exhibit 19: Viral conjunctivitis drugs market in APAC 2015-2020 ($ millions)
Exhibit 20: Global viral conjunctivitis drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 21: Impact of drivers
Exhibit 22: Impact of drivers and challenges
Exhibit 23: Akorn: YOY growth and revenue generated from ophthalmic segment 2011-2013 ($ millions)
Exhibit 24: Akorn: Key takeaways
Exhibit 25: Alcon: Business segmentation by revenue 2014
Exhibit 26: Alcon: YoY growth and revenue generated from sales of ophthalmic products 2011-2014 ($ billions)
Exhibit 27: Alcon: Key takeaways
Exhibit 28: Allergan: Key takeaways
Exhibit 29: Bausch & Lomb: Key takeaways
